Short- and long-term effects of dapagliflozin as an adjunct to insulin therapy in diabetic dogs: A pilot study
This pilot study demonstrates that adjunctive dapagliflozin therapy in insulin-treated diabetic dogs significantly improves short- and long-term glycemic control and reduces specific metabolic and cardiovascular markers with a generally favorable safety profile, despite requiring dietary adjustments to manage weight loss.